Systemic Therapy for Advanced Soft Tissue Sarcoma

Jennifer Sheng, Sujana Movva

Research output: Contribution to journalReview articlepeer-review

Abstract

Soft tissue sarcomas are rare tumors that present with distant metastasis in up to 10% of patients. Survival has improved significantly because of advancements in histologic classification and improved management approaches. Older agents such as doxorubicin, ifosfamide, gemcitabine, and paclitaxel continue to demonstrate objective response rates from 18% to 25%. Newer agents such as trabectedin, eribulin, aldoxorubicin, and olaratumab have demonstrated improvements in progression-free survival, overall survival, or toxicity profiles. Future studies on treatment of advanced soft tissue sarcoma will continue to concentrate on reducing toxicity, personalization of therapy, and targeting novel pathways.

Original languageEnglish (US)
Pages (from-to)1141-1156
Number of pages16
JournalSurgical Clinics of North America
Volume96
Issue number5
DOIs
StatePublished - Oct 1 2016

Keywords

  • Advanced soft tissue sarcoma
  • Chemotherapy
  • Novel therapies

ASJC Scopus subject areas

  • Surgery

Fingerprint Dive into the research topics of 'Systemic Therapy for Advanced Soft Tissue Sarcoma'. Together they form a unique fingerprint.

Cite this